AN2 Therapeutics Quote - ANTX

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.04

Bid

1.06

Offer

1.11

Volume

153,119

1.03 Day's Range 1.06

0.87 52 Week Range 22.22

Market Cap

31.036M

Previous Close

1.04

Open

1.05

Last Trade

1063

1.04

Last Trade Time

07:00:00

Financial Volume

US$ 159,838

VWAP

1.0439

Average Volume (3m)

632,452

Shares Outstanding

29,842,431

Dividend Yield

PE Ratio

-0.48

Earnings Per Share (EPS)

-2.17

Revenue

Net Profit

-64.73M

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.an2therapeutics.com

Headquarters

Dover, Delaware, USA

Founded

AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was US$1.04. Over the last year, AN2 Therapeutics shares have traded in a share price range of US$ 0.87 to US$ 22.22.

AN2 Therapeutics currently has 29,842,431 shares in issue. The market capitalisation of AN2 Therapeutics is US$31.04 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.02	-1.88679245283	1.06	1.09	1.03	117353	1.0535794	CS
4	-0.01	-0.952380952381	1.05	1.09	1.01	185277	1.05311874	CS
12	-1.47	-58.5657370518	2.51	3.07	0.87	632452	1.1554423	CS
26	-2.06	-66.4516129032	3.1	3.185	0.87	399494	1.51044179	CS
52	-13.62	-92.9058663029	14.66	22.22	0.87	328410	3.63120858	CS
156	-15.81	-93.8278931751	16.85	23.58	0.87	166543	5.42737872	CS
260	-15.81	-93.8278931751	16.85	23.58	0.87	166543	5.42737872	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
KXINKaixin Holdings	US$ 0.23 (27.78%)	1.61M
KZRKezar Life Sciences Inc	US$ 0.915 (23.65%)	3.75M
ICCTiCoreConnect Inc	US$ 0.41 (14.69%)	2.97M
ATXIAvenue Therapeutics Inc	US$ 2.20 (11.68%)	144
AQMSAqua Metals Inc	US$ 0.1594 (11.55%)	1.82k
HSDTHelius Medical Technologies Inc	US$ 0.4206 (-12.76%)	1.97k
CRDLCardiol Therapeutics Inc	US$ 1.73 (-11.73%)	148.96k
PIKKidpik Corporation	US$ 1.95 (-10.96%)	1.14k
NXLNexalin Technologies Inc	US$ 0.61 (-10.29%)	842.67k
SAGESage Therapeutics Inc	US$ 5.8001 (-9.80%)	2.03k
PBMPsyence Biomedical Ltd	US$ 0.115 (5.22%)	17.74M
GLUEMonte Rosa Therapeutics Inc	US$ 5.00 (0.00%)	5.71M
XPONExpion360 Inc	US$ 0.0299 (-0.66%)	4.75M
TIVCTivic Health Systems Inc	US$ 0.25 (-4.25%)	4.36M
KZRKezar Life Sciences Inc	US$ 0.915 (23.65%)	3.75M